Loading clinical trials...
Loading clinical trials...
This is a Phase 3 study designed to evaluate the safety and tolerability of two titration schedules for ALKS 5461.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Alkermes, Inc.
NCT07088380 · Major Depressive Disorder, Treatment Resistant Depression
NCT06843187 · Major Depressive Disorder(MDD), Insomnia Comorbid to Psychiatric Disorder
NCT06564818 · Major Depressive Disorder
NCT06110897 · Major Depressive Disorder
NCT04751331 · Major Depressive Disorder
Alkermes Investigational Site
Jacksonville, Florida
Alkermes Investigational Site
Orlando, Florida
Alkermes Investigational Site
Atlanta, Georgia
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions